Literature DB >> 22304369

Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples.

Mio Kitano1, Reza Rahbari, Erin E Patterson, Seth M Steinberg, Nijaguna B Prasad, Yongchun Wang, Martha A Zeiger, Electron Kebebew.   

Abstract

BACKGROUND: Thyroid cancer diagnosis in the United States has increased by 2.3-folds in the last three decades. Up to 30% of thyroid fine-needle aspiration biopsy (FNAB) results are inconclusive. Several differentially expressed microRNAs (miRNAs) have been identified as candidate diagnostic markers for thyroid nodules. We hypothesized that these differentially expressed miRNAs may improve the accuracy of FNAB in difficult to diagnose thyroid nodules.
METHODS: Expression levels of four miRNAs (miR-7, -126, -374a, and let-7g) were analyzed using quantitative real-time reverse transcription-polymerase chain reaction in 95 FNAB samples as the training set. A predictor model was formulated based on the most differentially expressed miRNA (miR-7) ΔCt value and the model was applied on a separate cohort of 59 FNAB samples as the validation set.
RESULTS: miR-7 was the best predictor to distinguish benign from malignant thyroid FNAB samples. The other three miRNAs were co-expressed and did not significantly contribute to the predictor model. miR-7 had a sensitivity of 100%, specificity of 29%, positive predictive value (PPV) of 36%, negative predictive value (NPV) of 100%, and overall accuracy of 76% when applied to the validation set. In subgroup analysis of preoperative nondiagnostic, indeterminate, or suspicious FNAB samples, the predictor model had an overall accuracy of 37% with sensitivity of 100%, specificity of 20%, PPV of 25%, and NPV of 100%.
CONCLUSIONS: miR-7 may be a helpful adjunct marker to thyroid FNAB in tumor types which are inconclusive. Given the high NPV of miR-7, a patient with a benign result based on the predictor model may be followed as opposed to performing an immediate diagnostic thyroidectomy. Future prospective clinical trials evaluating its accuracy in a larger cohort are warranted to determine its clinical utility.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22304369      PMCID: PMC3286806          DOI: 10.1089/thy.2011.0313

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  42 in total

1.  Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples.

Authors:  Haggi Mazeh; Ido Mizrahi; David Halle; Nadia Ilyayev; Alexander Stojadinovic; Barry Trink; Stella Mitrani-Rosenbaum; Marina Roistacher; Ilana Ariel; Ahmed Eid; Herbert R Freund; Aviram Nissan
Journal:  Thyroid       Date:  2011-02       Impact factor: 6.568

Review 2.  The functions of animal microRNAs.

Authors:  Victor Ambros
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

3.  The role of microRNA genes in papillary thyroid carcinoma.

Authors:  Huiling He; Krystian Jazdzewski; Wei Li; Sandya Liyanarachchi; Rebecca Nagy; Stefano Volinia; George A Calin; Chang-Gong Liu; Kaarle Franssila; Saul Suster; Richard T Kloos; Carlo M Croce; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

Review 4.  Predictors of thyroid tumor aggressiveness.

Authors:  O H Clark
Journal:  West J Med       Date:  1996-09

5.  miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation.

Authors:  Chen-Kai Chou; Rong-Fu Chen; Fong-Fu Chou; Hsueh-Wen Chang; Yi-Ju Chen; Ya-Fang Lee; Kuender D Yang; Jiin-Tsuey Cheng; Chao-Cheng Huang; Rue-Tsuan Liu
Journal:  Thyroid       Date:  2010-05       Impact factor: 6.568

6.  Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7.

Authors:  Rebecca J Webster; Keith M Giles; Karina J Price; Priscilla M Zhang; John S Mattick; Peter J Leedman
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

Review 7.  Thyroid fine-needle aspiration biopsy: progress, practice, and pitfalls.

Authors:  M Regina Castro; Hossein Gharib
Journal:  Endocr Pract       Date:  2003 Mar-Apr       Impact factor: 3.443

8.  MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions.

Authors:  Sirigiri Divijendra Natha Reddy; Kazufumi Ohshiro; Suresh K Rayala; Rakesh Kumar
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

Review 9.  Recent developments in predicting thyroid malignancy.

Authors:  Michael T Stang; Sally E Carty
Journal:  Curr Opin Oncol       Date:  2009-01       Impact factor: 3.645

10.  Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care.

Authors:  B Hamberger; H Gharib; L J Melton; J R Goellner; A R Zinsmeister
Journal:  Am J Med       Date:  1982-09       Impact factor: 4.965

View more
  21 in total

1.  MicroRNA expression profiles in differentiated thyroid cancer, a review.

Authors:  Xinying Li; Asim B Abdel-Mageed; Debasis Mondal; Emad Kandil
Journal:  Int J Clin Exp Med       Date:  2012-11-18

2.  Diagnostic value of microRNAs in discriminating malignant thyroid nodules from benign ones on fine-needle aspiration samples.

Authors:  Yang Zhang; Qi Zhong; Xiaohong Chen; Jugao Fang; Zhigang Huang
Journal:  Tumour Biol       Date:  2014-06-19

Review 3.  Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory.

Authors:  José Luis García-Giménez; Marta Seco-Cervera; Trygve O Tollefsbol; Carlos Romá-Mateo; Lorena Peiró-Chova; Pablo Lapunzina; Federico V Pallardó
Journal:  Crit Rev Clin Lab Sci       Date:  2017-12-11       Impact factor: 6.250

4.  Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology.

Authors:  Emmanuel Labourier; Alexander Shifrin; Anne E Busseniers; Mark A Lupo; Monique L Manganelli; Bernard Andruss; Dennis Wylie; Sylvie Beaudenon-Huibregtse
Journal:  J Clin Endocrinol Metab       Date:  2015-05-12       Impact factor: 5.958

5.  Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis.

Authors:  Zhihong Wang; Hao Zhang; Ping Zhang; Jing Li; Zhongyan Shan; Weiping Teng
Journal:  Med Oncol       Date:  2013-04-23       Impact factor: 3.064

Review 6.  MicroRNA-7: a promising new target in cancer therapy.

Authors:  Juanjuan Zhao; Yijing Tao; Ya Zhou; Nalin Qin; Chao Chen; Dan Tian; Lin Xu
Journal:  Cancer Cell Int       Date:  2015-10-29       Impact factor: 5.722

7.  Increased Pleiotrophin Concentrations in Papillary Thyroid Cancer.

Authors:  Youn Hee Jee; Samira M Sadowski; Francesco S Celi; Liqiang Xi; Mark Raffeld; David B Sacks; Alan T Remaley; Anton Wellstein; Electron Kebebew; Jeffrey Baron
Journal:  PLoS One       Date:  2016-02-25       Impact factor: 3.240

8.  miR-126-3p Inhibits Thyroid Cancer Cell Growth and Metastasis, and Is Associated with Aggressive Thyroid Cancer.

Authors:  Yin Xiong; Shweta Kotian; Martha A Zeiger; Lisa Zhang; Electron Kebebew
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

9.  Analysis options for high-throughput sequencing in miRNA expression profiling.

Authors:  Tomasz Stokowy; Markus Eszlinger; Michał Świerniak; Krzysztof Fujarewicz; Barbara Jarząb; Ralf Paschke; Knut Krohn
Journal:  BMC Res Notes       Date:  2014-03-13

10.  miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.

Authors:  Chen-Tian Shen; Zhong-Ling Qiu; Hong-Jun Song; Wei-Jun Wei; Quan-Yong Luo
Journal:  J Exp Clin Cancer Res       Date:  2016-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.